H1 secures $40M from CVS, proving SaaS startups can still attract investment

At a glance:

• H1 secures $40M investment from CVS Health Ventures for its healthcare data platform
• Nine-year-old company focuses on physician information sales to pharma, hospitals, and insurers
• Achieved cash flow and EBITDA profitability while projecting over 40% growth this year

What happened

H1, a nine-year-old healthcare data platform, has secured a $40 million investment from CVS Health Ventures, the corporate venture capital arm of CVS Health and Aetna. The funding comes at a time when pre-AI era SaaS startups are struggling to attract investor attention amid the artificial intelligence boom. CEO Ariel Katz emphasized that H1 wasn't actively seeking capital, having achieved cash flow and EBITDA profitability last year, but the strategic partnership opportunity with one of the largest healthcare companies globally proved compelling.

The investment validates Katz's argument that not all SaaS companies should be grouped together in the current investment climate. While workflow-focused SaaS businesses may be vulnerable to AI disruption, Katz contends that data providers like H1 occupy a different category entirely. He specifically noted that he doesn't worry about AI models like Anthropic's Claude replicating H1's core business, suggesting instead that such AI companies might become customers rather than competitors.

Why it matters

The funding round highlights a growing divide in the venture capital landscape between AI-native startups commanding sky-high valuations and traditional SaaS companies that have been largely overlooked. Traditional VCs have become increasingly focused on backing AI startups, leaving profitable SaaS businesses with strong fundamentals struggling to secure follow-on funding despite their proven track records.

However, corporate venture arms appear to see value where traditional VCs do not. CVS Health Ventures' decision to lead this round suggests that industry-specific data platforms may still hold significant strategic value, particularly in healthcare where data quality and comprehensiveness remain paramount. This could indicate a shift toward more targeted, vertical-focused investments as corporate strategics seek to strengthen their data capabilities.

Company background

H1's business model centers on collecting and selling detailed information about physicians to pharmaceutical companies, hospital systems, and health insurers. This positions the company as a data provider rather than a workflow automation tool, which Katz argues makes it less susceptible to AI-driven disruption. The company's focus on comprehensive physician data globally has created what Katz believes is a defensible moat in the healthcare information space.

The startup was last valued at $750 million when it raised $100 million in November 2021 during the height of the Covid-era tech bubble, led by Altimeter Capital. Like many companies that secured funding just before the 2022 valuation downturn, H1 has since prioritized profitability and growth through strategic acquisitions of smaller competitors and complementary businesses rather than pursuing additional venture funding.

Looking ahead

With this new investment from CVS Health Ventures, H1 plans to accelerate its growth trajectory while maintaining its profitability focus. The partnership provides not just capital but also strategic access to one of the largest healthcare ecosystems in the United States, potentially opening new distribution channels and data sources.

Katz's vision suggests that rather than competing with AI companies, H1 could become a critical data supplier for AI model training and enhancement. This positions the company to benefit from the AI revolution rather than being displaced by it, creating a symbiotic relationship between traditional data providers and emerging AI technologies. The company's ability to maintain strong financial performance while navigating the post-2021 funding environment demonstrates resilience that may attract additional strategic investors.

The healthcare data market continues expanding as digital transformation accelerates across the sector. H1's proven business model and recent profitability achievement suggest that well-positioned SaaS companies can still command significant investment, particularly when they offer specialized, high-quality data assets that complement rather than compete with emerging AI technologies.